Taurus becomes new marketing partner for Medigene's drug Veregen® in Germany
05 Dezembro 2013 - 4:31AM
Medigene AG / Taurus becomes new marketing partner for
Medigene's drug Veregen® in Germany . Processed and transmitted by
NASDAQ OMX Corporate Solutions. The issuer is solely responsible
for the content of this announcement.
Target group
enlargement is expected to increase
sales revenue
Martinsried/Munich, 05.
December 2013. Medigene AG (MDG, Frankfurt, Prime
Standard) announces that its drug Veregen® for the
treatment of genital warts will be marketed by the company's new
partner Taurus Pharma GmbH, Germany beginning in January 2014.
Medigene, the current partner Abbott, and the pharmaceutical
company Taurus Pharma GmbH have jointly agreed on this. The new
marketing partner will add the dermatologists, who represent an
important group of specialists to treat this skin disease, to
Veregen® target group.
The partners anticipate that this will bring about an increase in
sales of the prescription drug. In Austria and Switzerland,
Veregen® will continue
to be distributed by Medigene's partner Abbott in the future.
Dr. Frank
Mathias, Chief Executive Officer of
Medigene, comments: "The new partnership is a gain for
Veregen® and
beneficial for the affected patients. Thanks to many years of
experience in both fields, Taurus will sell our drug not only to
gynecologists, as has been the case until now, but equally to
dermatologists. This will further expand the reach for
Veregen®."
Klaus
Seliger, Managing Director of Taurus Pharma
GmbH, adds:
"Veregen® ideally adds
to both our dermatology as well as the gynecology portfolios. Hence
Veregen® will play a
key role in our sales activities. We look forward to providing as
many patients as possible with this innovative and reliable drug,
by extensively informing the two major physician groups treating
patients that suffer from external genital warts about the
efficacious therapeutic option Veregen®."
Apart from the German-speaking
countries, Veregen® is also
available in the USA (distributed by Fougera), Spain (Bial), Serbia
(Pharmanova), the Netherlands (Will-Pharma), and Taiwan (SynCore)
and has been approved in a number of additional countries. Medigene
expects the launch of Veregen® in other
countries within the next few months. Several marketing partnership
agreements have been concluded in Europe, Asia, and America.
Medigene is planning to continue this global licensing strategy to
further tap the product's market potential.
Veregen®: Veregen®, a topical
treatment for external genital or perianal warts, contains a
concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment
guidelines for sexually transmitted diseases, the US Center for
Disease Control and Prevention recommends Sinecatechins 15%
ointment (Veregen®) as a
possible option for treating genital warts. In addition,
Sinecatechins 10% & 15% ointments (Veregen®) have
been included in the current European guideline on the treatment of
genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Taurus
Pharma: Taurus Pharma GmbH, headquartered in Bad Homburg
vor der Höhe, Germany, has been selling pharmaceuticals in Germany
for more than 25 years. As a member of the Poli Group Holding,
Taurus Pharma benefits from the research and development work done
by this globally operating group of companies. Shareholders and
employees are working on adding high-quality products that provide
true help for the patients in the treatment of their diseases. For
this purpose, Taurus Pharma develops and distributes an attractive
range of prescription and OTC drugs. The company's focus is on
gynecology and dermatology. For more detailed information, please
visit www.tauruspharma.de.
Medigene
AG (Frankfurt: MDG, prime standard) is a publicly listed
biotechnology company headquartered in Martinsried/Munich, Germany.
Medigene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases. Medigene was the
first German biotech company to have revenues from marketed
products, which are distributed by partner companies. It has two
drug candidates in clinical trials, EndoTAG®-1 and
RhuDex®, and is
developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and Veregen® are registered trademarks of
Medigene AG. Polyphenon E® is a trademark of Mitsui
Norin Co., Ltd. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia
Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medigene AG via Globenewswire
HUG#1747806
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
